Chronic hepatitis B (CHB) results from the inability of the host’s immune system to control viral replication. Interferon-α (IFN-α) therapy can convert CHB into inactive hepatitis B virus (HBV) infection in 20–30% of the treated patients. In spite of the low response rate, IFN-α therapy has the advantage of having a limited duration and being effective even after therapy, as demonstrated by a m...

Introduction : - Immune response may be affected by anesthesia and sedation. In anesthesia, the immue is temporary as used for short time. However, immune more obvious in critical illness patients because of long time Diprivan dormicum are two commonly medications sedation analgesia care unit patients. Dipravan a good medication surgical unit. Dormicum unit, usually producing prolonged when Pat...

Little is known about the optimal treatment following the initial failure of interferon therapy and the potential different efficacy with de novo therapy with entecavir (ETV) or telbivudine (LDT) and following the interferon therapy failure.ETV or LDT therapy following the interferon therapy failure was compared with that of de novo therapy with ETV or LDT in patients with chronic hepatitis B v...

Two murine models, C3H 38C13 B-cell lymphoma and AKR SL2 I cell lymphoma were used to determine the efficacy of three different Interferon preparations, recombinant human hybrid interferon-a A/D, recombinant murine Interferon (rMIFN)-7, and natural MIFN-a//3 (>85% ß), alone and in combination with tumor specific and nonspecific monoclonal antibody therapy. All three Interferon preparations hav...

Chronic hepatitis B (CHB) results from the inability of the host's immune system to control viral replication. Interferon-α (IFN-α) therapy can convert CHB into inactive hepatitis B virus (HBV) infection in 20-30% of the treated patients. In spite of the low response rate, IFN-α therapy has the advantage of having a limited duration and being effective even after therapy, as demonstrated by a m...

This paper reviews the results of recent studies carried out in the USA on the treatment of chronic hepatitis B with interferon alfa-2b. In the US multicentre trial, 37% of patients lost hepatitis B e antigen (HBeAg) and hepatitis B virus (HBV)-DNA when treated with 5 million units (MU) daily for 16 weeks, compared to 42% in the US National Institutes of Health (NIH) trial treated with 10 MU th...

In this pilot study of the effects of interferon alfa in 10 anti-HIV positive, chronic hepatitis B patients treated with zidovudine (AZT), tolerance to interferon was good and similar to that in anti-HIV negative patients. After treatment, the HIV stage and CD4 lymphocyte count were unchanged. In two patients hepatitis B virus (HBV)-DNA and hepatitis B e antigen (HBeAg) disappeared and the seru...

BACKGROUND Hepatitis C is an epidemic worldwide since discovery in 1989. Conventional interferon alpha-2b plus Ribavirin therapy was started in 1998 but over all sustained viral response (SVR) rates are much below the desired rates to eradicate the diseases and stopping its epidemic. This study was conducted to access the therapeutic and cost-effectiveness of long acting pegylated interferon al...

Introduction: Renewal of Interest in the Treatment of Chronic Hepatitis B Antiviral therapy studies of hepatitis B were first published in the mid 1970s, nearly a decade before the first treatment trials were reported for hepatitis C. Yet much of the emphasis on antiviral therapy in the United States until very recently has been focused on the treatment of hepatitis C. This is due to a number o...